AnalystBook Research · Company Intelligence

Chewy, Inc.

CHWYNYSE

Built from Chewy, Inc.'s own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

Chewy lifted revenue and FCF, but net income fell.

The read at a glance✓ Audited against SEC data
  • Business mixOnline pet retail and healthNote
  • Revenue$12.6B, +6.2%OK
  • FCF$562.4M, +24.3%OK
  • Net income$222.8M, -43.3%Watch
  • MarginsGross margin 29.8%, +55 bpsOK
  • Altman/Beneish/EQAll clear in FY2026 rowsOK
  • Insiders0 purchases / 17 salesWatch

Business

Chewy is an online pet-products, supplies, prescriptions, and pet-health platform with about 4,000 brands and about 190,000 products and service offerings.

Where the revenue comes from

Fiscal 2025, as Chewy, Inc. reports it. History and quarterly detail are in the app.

  • Reportable$12.6B

Leadership changes

From Chewy, Inc.'s own filings, the day they're filed.

  • William Billings · Chief Accounting Officer · appointmenteff. 2026-02-23
  • David Reeder · CAO · appointmenteff. 2024-07-22
  • Stacy Bowman · Chief Accounting Officer · departureeff. 2024-07-18

Latest filings

  • 8-K · Company announcement2026-07-13
  • 8-K · Company announcement2026-06-24
  • 8-K · Company announcement2026-06-10
  • 10-Q · Quarterly report2026-06-10
  • DEF 14A · Annual proxy (pay & governance)2026-05-22
In the full recordFree for 14 days
  • What changed🔒
  • Insider signal🔒
  • Growth quality🔒
  • Margins & accounting🔒
  • Capital allocation🔒
  • Real risks🔒
  • The long arc🔒
  • Company history🔒
  • Main tension🔒
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about Chewy, Inc., every answer cited to the official filings🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

14-day free trial, no credit card. For research purposes only; not investment advice.